Patrick M. Forde

Also affiliated with Johns Hopkins University, Trinity College, Trinity College Dublin, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

4.0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 37 papers — median percentile 94. Top paper: “Association between pathologic response and survival after neoadjuvant therapy in lung cancer”.

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Nature Medicine(2023)10.1038/s41591-023-02660-6

N/A

4.9DataRank · unranked

167 citations

Ashley Cimino‐Mathews, Elizabeth D. Thompson, Mariano Provencio, Patrick M. Forde, Jonathan Spicer +19 more

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Nature Medicine(2021)10.1038/s41591-021-01541-0

N/A

3.9DataRank · unranked

137 citations

Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs +22 more

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002473

N/A

2.5DataRank · unranked

67 citations

Karisa C. Schreck, Wei Fu, Chen Hu, Alexander Carvajal-González, Roisín M. Connolly +18 more

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

Nature(2021)10.1038/s41586-021-03752-4

N/A

0.948DataRank · unranked

555 citations

Jiajia Zhang, Zhicheng Ji, Ajay Vaghasia, Boyang Zhang, Emily Han-Chung Hsiue +50 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Persistent mutation burden drives sustained anti-tumor immune responses

Nature Medicine(2023)10.1038/s41591-022-02163-w

N/A

0.747DataRank · unranked

144 citations

Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M. Shao +16 more

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Nature Medicine(2025)10.1038/s41591-025-03958-3

N/A

0.441DataRank · unranked

15 citations

Paul K. Lee, Reza J. Mehran, Chen Hu, Suqi Ke, Amna Jamali +24 more

[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy

Journal of Nuclear Medicine(2024)10.2967/jnumed.124.268253

N/A

0.341DataRank · unranked

6 citations

Millie Das, Minal Vasanawala, Deepti Behl, Martin G. Pomper, Patrick M. Forde +12 more

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Frontiers in Oncology(2022)10.3389/fonc.2022.945798

N/A

0DataRank · unranked

13 citations

Xiaoshan M. Shao, Noushin Niknafs, Archana Balan, Gavin Pereira, Kristen A. Marrone +12 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps8598

N/A

0DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Vinicius Ernani, Patrick M. Forde, Liza C. Villaruz +12 more

Lung tumor-infiltrating T reg have divergent transcriptional profiles and function linked to checkpoint blockade response

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.12.13.520329

N/A

0DataRank · unranked

0 citations

Jiajia Zhang, Boyang Zhang, Laurene S. Cheung, Zhen Zeng, Christopher Cherry +32 more

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.07.011

N/A

0DataRank · unranked

288 citations

Patrick M. Forde, Leisha A. Emens, Mark Yarchoan, Kellie N. Smith, Drew M. Pardoll +1 more

Lung tumor–infiltrating Treghave divergent transcriptional profiles and function linked to checkpoint blockade response

Science Immunology(2023)10.1126/sciimmunol.adg1487

N/A

0DataRank · unranked

75 citations

Jiajia Zhang, Laurene S. Cheung, Sydney Connor, Boyang Zhang, Zhen Zeng +34 more

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2994

N/A

0DataRank · unranked

69 citations

Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis M. Taube +12 more

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1469

N/A

0DataRank · unranked

34 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +28 more

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

Annals of Oncology(2023)10.1016/j.annonc.2023.10.053

N/A

0DataRank · unranked

19 citations

Patrick M. Forde, J.D. Spicer, C. Wang, Shun Lu, Tetsuya Mitsudomi +15 more

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007188

N/A

0DataRank · unranked

9 citations

Peter B. Illei, Bradley Presson, Dipika Singh, Zhen Zeng, Mara Lanis +12 more

Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.23.546338

N/A

0DataRank · unranked

3 citations

Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs +25 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps8603

N/A

0DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Panos Savvides, Liza C. Villaruz, Patrick M. Forde +12 more

Data from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6533117.v1

N/A

0DataRank · unranked

0 citations

Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis M. Taube +12 more

The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

The Annals of Thoracic Surgery(2024)10.1016/j.athoracsur.2024.01.024

N/A

0DataRank · unranked

35 citations

Cameron N. Fick, James M. Isbell, Jamie E. Chaft, Nasser K. Altorki, Bernard J. Park +13 more

Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS- Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2983

N/A

0DataRank · unranked

14 citations

Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang, Isha Gurumurthy +24 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928

N/A

0DataRank · unranked

16 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

Clinical development of immuno-oncology therapeutics

Cancer Letters(2025)10.1016/j.canlet.2025.217616

N/A

0DataRank · unranked

44 citations

Qi Chen, Qiang Shan, Tingbo Liang, Patrick M. Forde, Lei Zheng +1 more

A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types

Nature Communications(2025)10.1038/s41467-024-55059-3

N/A

0DataRank · unranked

13 citations

Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor, Boyang Zhang +14 more

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

Non-coding RNA Research(2025)10.1016/j.ncrna.2025.02.003

N/A

0DataRank · unranked

4 citations

Suguru Yamauchi, Kaitlyn Ecoff, Kristen Rodgers, James R. Eshleman, Charles Conover Talbot +7 more

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001282

N/A

0DataRank · unranked

166 citations

Valsamo Anagnostou, Tricia R. Cottrell, Kellie N. Smith, Franco Verde, Marianna Zahurak +27 more

Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis

Arthritis Research & Therapy(2025)10.1186/s13075-025-03546-3

N/A

0DataRank · unranked

5 citations

Ami A. Shah, Clifton O. Bingham, Jennifer H. Elisseeff, Joseph C. Murray, Julie R. Brahmer +5 more

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Nature Communications(2021)10.1038/s41467-021-24994-w

N/A

0DataRank · unranked

480 citations

Jakob Sidenius Johansen, Stephen Cristiano, Jamie E. Medina, Jillian Phallen, Klaus Richter Larsen +33 more

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100220

N/A

0DataRank · unranked

15 citations

Emily Brigham, Kevin J. Psoter, Khinh Ranh Voong, Bairavi Shankar, David S. Ettinger +16 more

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004688

N/A

0DataRank · unranked

139 citations

Jenna VanLiere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid +22 more

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

The Journal of Experimental Medicine(2022)10.1084/jem.20212169

N/A

0DataRank · unranked

49 citations

Andrew Chow, Levi Mangarin, Heng Pan, Jiajia Zhang, Nicholas Ceglia +21 more

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100384

N/A

0DataRank · unranked

50 citations

Chunnan Liu, Patrick M. Forde, Chen Hu, Samuel Rosner

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors

Cancer Immunology Immunotherapy(2022)10.1007/s00262-022-03169-6

N/A

0DataRank · unranked

30 citations

Joell J. Gills, Fuad Mohammad, James R. White, Courtney Stevens, Hua Ding +15 more

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

The Oncologist(2022)10.1093/oncolo/oyac140

N/A

0DataRank · unranked

20 citations

Joseph C. Murray, Kevin J. Psoter, Jiajia Zhang, Durrant Barasa, Julie R. Brahmer +14 more

Patrick M. Forde

Indexed papers

Top data-sharing exemplar

Papers